Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castration Sensitive Prostate Cancer (mCSPC)”

17 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 17 results

Large-scale testing (Phase 3)Looking for participantsNCT07028853
What this trial is testing

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer (mCSPC)Hormone Sensitive Prostate CancerProstate Cancer+1 more
Pfizer 1,000
Large-scale testing (Phase 3)Active Not RecruitingNCT04497844
What this trial is testing

Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 696
Early research (Phase 1)Looking for participantsNCT04729114
What this trial is testing

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration Resistant Prostate CancerMetastatic Castration-sensitive Prostate Cancer
Astellas Pharma Global Development, Inc. 174
Large-scale testing (Phase 3)Looking for participantsNCT07723248
What this trial is testing

Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
ORIC Pharmaceuticals 600
Post-approval studies (Phase 4)UnknownNCT04601441
What this trial is testing

Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan

Who this might be right for
Metastatic Castration-sensitive Prostate Cancer
Kindai University 100
Not applicableLooking for participantsNCT06429813
What this trial is testing

Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)

Who this might be right for
Castrate Sensitive Prostate CancerMetastatic Prostate Cancer
Paul Viscuse 24
Not applicableStudy completedNCT06072196
What this trial is testing

Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Who this might be right for
Prostatic Neoplasms
Pfizer 3,017
Large-scale testing (Phase 3)Active Not RecruitingNCT05884398
What this trial is testing

An Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

Who this might be right for
Metastatic Castrate-sensitive Prostate Cancer
Janssen Research & Development, LLC 420
Large-scale testing (Phase 3)Active Not RecruitingNCT04821622
What this trial is testing

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Who this might be right for
Prostate Cancer
Pfizer 599
Early research (Phase 1)Study completedNCT04666129
What this trial is testing

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate CancerMetastatic Castration-Sensitive Prostate CancerNon-Metastatic Castration-Resistant Prostate Cancer
Sumitomo Pharma America, Inc. 48
Not applicableStudy completedNCT07086651
What this trial is testing

Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer (mCSPC)Cancer of the ProstateProstate Neoplasms+1 more
Pfizer 1,300
Not applicableNot Yet RecruitingNCT07779590
What this trial is testing

Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Pfizer 4,700
Large-scale testing (Phase 3)Study completedNCT04887506
What this trial is testing

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate CancerMetastatic Castration-sensitive Prostate CancerMetastatic Prostate Cancer
Tavanta Therapeutics 107
Not applicableStudy completedNCT06151418
What this trial is testing

Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

Who this might be right for
Prostatic Neoplasms
Pfizer 2,313
Not applicableStudy completedNCT05701007
What this trial is testing

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer (mCSPC)Metastatic Castration Resistant Prostate Cancer (mCRPC)
Pfizer 1,083
Large-scale testing (Phase 3)WithdrawnNCT05771896
What this trial is testing

Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC

Who this might be right for
Metastatic Prostate Cancer
GenesisCare USA
Large-scale testing (Phase 3)Active Not RecruitingNCT06120491
What this trial is testing

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

Who this might be right for
Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca 1,898